Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31054151 | 1.00 | HTR2A (0.55) | HTR2AHTR2CSLC6A2TAAR1SLC6A4 | |
| SCHEMBL31054201 | 1.00 | HTR2A (0.55) | HTR2AHTR2CSLC6A2TAAR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL1191449 | 0.98 | HTR2A (0.54) | HTR2AHTR2CSLC6A2TAAR1SLC6A4 | |
| SCHEMBL20495645 | 0.85 | CYP1A2 (0.47) | HTR2AHTR2CSIGMAR1CYP1A2CYP2C19 | |
| SCHEMBL30119544 | 0.85 | CYP1A2 (0.47) | HTR2AHTR2CSIGMAR1CYP1A2CYP2C19 | |
| SCHEMBL331127 | 0.83 | GABRA1 (0.54) | SIGMAR1CYP1A2CYP2C19CYP2D6CTNNB1 | |
| SCHEMBL3681421 | 0.83 | CYP1A2 (0.52) | SLC6A4SIGMAR1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL7528890 | 0.83 | CYP1A2 (0.53) | SLC6A4SIGMAR1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL24548553 | 0.83 | CTNNB1 (0.53) | CTNNB1 | |
| SCHEMBL16449785 | 0.83 | CTNNB1 (0.53) | CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | claimed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | claimed |
| CN-102170874-A | Compositions and methods for treating psychiatric disorders | GOSFORTH CT HOLDINGS PTY LTD | 2011-08-31 | — | — | CN | claimed |
| US-7470812-B2 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-30 | — | — | US | claimed |
| US-7465826-B2 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-16 | — | — | US | claimed |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | KANSAL VINOD K | 2008-02-28 | — | — | US | claimed |
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | KANSAL VINOD K | 2008-02-21 | — | — | US | claimed |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL USA, INC. | 2007-08-16 | — | — | US | claimed |
| EP-1802568-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-04 | — | — | EP | claimed |
| WO-2007035789-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-29 | — | — | WO | claimed |
| CN-110114368-B | Targeted mutant interferon-gamma and uses thereof | 奥睿尼斯生物科学私人有限公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-3455203-B1 | VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS | RES TRIANGLE INST (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10899699-B2 | Vinylogous phenethylamines as neurotransmitter releasers | RESEARCH TRIANGLE INSTITUTE (US) | 2021-01-26 | — | — | US | disclosed |
| EP-1045025-A1 | (S)-alpha-PHENETHYLAMINE : PYRUVATE TRANSAMINASE | KANEKA CORPORATION (JP) | 2000-10-18 | — | — | EP | disclosed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | GABRE, GABRA5, GABRA6 | HTR2A 353/4885HTR2C 242/4885SLC6A2 2357/4885 |
| US-10899699-B2 | Vinylogous phenethylamines as neurotransmitter releasers | SLC18A2, SLC6A2, SLC18A3 | HTR2A 10/4885HTR2C 11/4885SLC6A2 2/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | HTR2A 3241/4885HTR2C 2540/4885SLC6A2 4706/4885 |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | HTR2A 353/4885HTR2C 242/4885SLC6A2 2357/4885 |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | BRCA1, VHL, TP53 | HTR2A 3785/4885HTR2C 4143/4885SLC6A2 2466/4885 |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | HTR2A 353/4885HTR2C 242/4885SLC6A2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.